THE ANTI IL-23/IL-12 AGENT USTEKINUMAB IS AN EFFECTIVE AND SAFE INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE REFRACTORY OR INTOLERANT TO ANTI-TNF: A MULTICENTRE ITALIAN STUDY

Alessandro Gubbiotti  ¹     Brigida Barberio  ¹     Fabiana Zingone  ¹     Lorenzo Bertani  ²     Antonio Ferronato  ³     Renato Sablich  ⁴     Maria Teresa Urbano  ⁴     Maria Giulia Demarzo  ⁵     Giorgia Bodini  ⁵     Andrea Buda  ⁶     Davide Massimi  ⁶     Cesare Casadei  ⁶     Linda Cingolani  ⁶     Greta Lorenzon  ⁶     Renata D'Incà  ⁶     Edoardo Vincenzo Savarino  ^6    
1 University of Padua, Padua, Italy
² University of Pisa, Pisa, Italy
³ Azienda ULSS 7 Pedemontana, Santorso (Vi), Italy
⁴ Ospedale S.Maria degli Angeli, Pordenone, Italy
⁵ Policlinico San Martino, Genova, Italy
⁶ UOC Gastroenterology, Feltre, Italy

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)